Literature DB >> 27995084

Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment.

Masatoshi Kudo1, Franco Trevisani2, Ghassan K Abou-Alfa3, Lorenza Rimassa4.   

Abstract

Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate.

Entities:  

Keywords:  Hepatocellular carcinoma; Practice guideline; Treatment; Treatment algorithm

Year:  2016        PMID: 27995084      PMCID: PMC5159738          DOI: 10.1159/000449343

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  34 in total

1.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

2.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

4.  Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

Authors:  S Giambartolomei; F Covone; M Levrero; C Balsano
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

5.  Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

Authors:  Guan-Tarn Huang; Po-Huang Lee; Yuk-Ming Tsang; Ming-Yang Lai; Pei-Ming Yang; Rey-Heng Hu; Pei-Jer Chen; Jia-Horng Kao; Jin-Chuan Sheu; Cha-Ze Lee; Ding-Shinn Chen
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316

9.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Authors:  Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Erin B Kennedy; Ghassan Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; E Claire Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  37 in total

1.  Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Naoko Kamo; Toshimi Kaido; Shintaro Yagi; Hideaki Okajima; Shinji Uemoto
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

2.  IVIM improves preoperative assessment of microvascular invasion in HCC.

Authors:  Yi Wei; Zixing Huang; Hehan Tang; Liping Deng; Yuan Yuan; Jiaxing Li; Dongbo Wu; Xiaocheng Wei; Bin Song
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

3.  MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.

Authors:  Long Yang; Zheyue Yuan; Yamin Zhang; Zilin Cui; Yang Li; Jiancun Hou; Xiaolong Liu; Zirong Liu; Rui Shi; Qing Tian; Jian Wang; Lianjiang Wang
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

4.  Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma.

Authors:  Junichi Shindoh; Yusuke Kawamura; Yuta Kobayashi; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Masaji Hashimoto
Journal:  J Gastrointest Surg       Date:  2019-06-12       Impact factor: 3.452

5.  Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma.

Authors:  Yosuke Miyachi; Toshimi Kaido; Siuan Yao; Hisaya Shirai; Atsushi Kobayashi; Yuhei Hamaguchi; Naoko Kamo; Shintaro Yagi; Shinji Uemoto
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

6.  Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma.

Authors:  Yung-Chang Lin; Chen-Yu Hsu; Sheng-Kai Huang; Yun-Han Fan; Chien-Hao Huang; Chan-Keng Yang; Wan-Ting Su; Po-Chia Chang; Avijit Dutta; Yu-Jen Liu; Ching-Tai Huang; Tse-Ching Chen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2018-09-19       Impact factor: 8.110

Review 7.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 8.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

9.  Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonio Daniele Pinna; Benjamin Djulbegovic; Federico Mazzotti; Luigi Bolondi
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740

10.  Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma.

Authors:  Chuantao Zhang; Jianxiang Liu; Zhiyi Han; Xiang Cui; Deti Peng; Yufeng Xing
Journal:  Int J Clin Oncol       Date:  2020-04-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.